Company: INMB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001213900-25-073077
Chunk: 1

Company: Inmune Bio, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
     22 
  
    Additional paid-in capital 
     226,904  
     195,754 
  
    Accumulated other comprehensive loss 
     (763) 
     (575)
  
    Accumulated deficit 
     (197,301) 
     (163,104)
  
    TOTAL STOCKHOLDERS’ EQUITY 
     28,867  
     32,097 

    TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY 
    $37,684  
    $39,562 

The accompanying notes are an integral part of
these unaudited condensed consolidated financial statements.

1

INMUNE BIO INC. 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS

(In thousands, except share and per share amounts)

(Unaudited)

    For the Three Months Ended June 30,  
    For the Six Months Ended  June 30, 

    2025  
    2024  
    2025  
    2024 
  
    REVENUE 
    $-  
    $-  
    $50  
    $14 

    OPERATING EXPENSES 

    General and administrative 
     2,253  
     2,812  
     4,569  
     5,150 
  
    Research and development 
     5,804  
     7,053  
     13,443  
     15,746 
  
    Impairment of acquired in-process research and development intangible assets 
     16,514  
     -  
     16,514  
     - 
  
    Total operating expenses 
     24,571  
     9,865  
     34,526  
     20,896 

    LOSS FROM OPERATIONS 
     (24,571) 
     (9,865) 
     (34,476) 
     (20,882)

    OTHER INCOME, NET 
     113  
     119  
     279  
     111 

    NET LOSS 
    $(24,458) 
    $(9,746) 
    $(34,197) 
    $(20,771)

    Net loss per common share – basic and diluted 
    $(